Vestipitant

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Vestipitant
(IUPAC) ime
(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Klinički podaci
Identifikatori
CAS broj 334476-64-1
ATC kod nije dodeljen
PubChem[1][2] 9832383
Hemijski podaci
Formula C23H21F10N3O 
Mol. masa 545.416 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Vestipitant je razvio GlaksoSmitKlajn. Ovaj lek deluje kao selektivni antagonist za NK1 receptor. On je u razvoju kao potencijalni antiemetik i anksiolitik[3][4], i kao lek za tinitus.[5]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy 3 (3): 140–2. PMID 18632487. doi:10.3816/SCT.2006.n.011. 
  4. Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; Olivier, B (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. PMID 18657401. doi:10.1016/j.euroneuro.2008.06.002. 
  5. Clinical Trials NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss

Vidi još[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).